| Literature DB >> 35928349 |
Dauren Auzhanov1, Meirbek Aimagambetov1, Nazarbek Omarov1.
Abstract
The cause of all small bowel obstruction in 60-75% of cases is adhesive development. The first and main method for adhesion prevention is undoubtedly the surgical technique, but the prevention of adhesive development is still actual. We aimed to study macroscopic and microscopic peculiarities of the intestine, peritoneum, and scars of the anterolateral abdominal wall. Also, immunological blood changes were observed in rats with the experimental created adhesive disease on the background of azathioprine introduction. The experiment was conducted on 40 rats divided into 2 subgroups: 20 animals as an experimental group (EG1) and 20 as a control group (CG1). Animals from EG received azathioprine (Moshimerampreparaty named by N.A. Semashko, Russia) in a dosage of 1 mg/100g of weight once a day for the first 3 days (starting from the day of surgery). The control group did not receive any drugs. All 40 rats survived the postoperative period. Rats were removed from the experiment on the 7th day after the operation. There were significant statistical differences in most indicators between the experimental and control groups. Phagocytic index (PI) was reduced by 4.55 due to the natural reaction of the rat organism to the surgery. Indicators of EG were a slight decrease in leukocytes and lymphocytes by 0.3 and 0.9, respectively, a moderate decrease in T-lymphocytes by no more than 2.0, and a decrease in phagocytic activity by 5.8. Immunosuppression with azathioprine significantly reduced the frequency and severity of the adhesive process of the abdominal cavity. Used in the recommended dose does not significantly inhibit important indicators of immunity and does not affect wound healing processes. ©2022 JOURNAL of MEDICINE and LIFE.Entities:
Keywords: CG – control group; EG – experimental group; PI – phagocytic index; adhesive disease; azathioprine; blood changes; postoperative period; scars
Mesh:
Substances:
Year: 2022 PMID: 35928349 PMCID: PMC9321496 DOI: 10.25122/jml-2021-0371
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Evaluation scale for fibrosis and inflammation.
| Description | Points |
|---|---|
|
| |
| No | 0 |
| Minimal, loose | 1 |
| Middle | 2 |
| Pronounced, dense | 3 |
|
| |
| No | 0 |
| Giant cells, random scattered lymphocytes and plasma cells | 1 |
| Giant cells with an increased number of mixed lymphocytes, plasma cells, eosinophils, neutrophils | 2 |
| A lot of mixed inflammatory cells, microabscesses | 3 |
Moreno scale. Quantification of adhesion formation in rat groups.
| Criteria | Control group 1, n=20 | Experimental group 1, n=20 | U | Z | R |
|---|---|---|---|---|---|
|
| 50 | 15 | 5.0 | -5.480 | <0.001 |
|
|
|
| |||
|
| |||||
|
| 31 | 13 | 19.333 | 2 | <0.001 |
|
| |||||
|
| 31 | 3 | 25.342 | 2 | <0.001 |
|
| |||||
|
| - | - | - | - | - |
Binda scale.
| Degree of adhesion | Points | Extent (animals number) | Type of adhesions (adhesions number) | Tenacity (adhesions number) | |||
|---|---|---|---|---|---|---|---|
| CG (n=20) | EG (n=20) | CG (n=50) | EG (n=15) | CG (n=50) | EG (n=15) | ||
|
| 0 | 0 | 6 | - | 3 | - | 3 |
| 1 | 3 | 14 | 2 | 13 | 12 | 13 | |
|
| 2 | 10 | - | 21 | 2 | 17 | 2 |
| 3 | 7 | - | 27 | - | 21 | - | |
| χ2-26.189; df-1, p<0.001 | F-0.00000, p<0.05 | χ2-20; 407; df-1, p<0.001 | |||||
χ2 – chi-test with Yates correction; F – exact Fisher Criterion.
The degree of fibrosis and inflammation.
| Points | CG (n=20) | EG (n=20) | χ2 | df | R |
|---|---|---|---|---|---|
|
| |||||
| 0 | 0 | 3 | 4.949 | 1 | 0.027 |
| 1 | 5 | 10 | |||
|
| 5 | 13 | |||
| 2 | 10 | 7 | |||
| 3 | 5 | 0 | |||
|
| 15 | 7 | |||
|
| |||||
| 0 | 1 | 3 | 0.909 | 1 | 0.341 |
| 1 | 9 | 10 | |||
|
| 9 | 13 | |||
| 2 | 10 | 7 | |||
| 3 | 1 | 0 | |||
|
| 11 | 7 | |||
χ2 – Yates correction chi-test.
Indicators of the immune status of rats.
| Indicators | Norm (Me) | CG. (Me) | EG. (Me) | U C.G.* E.G. | U C.G.* Norm | U EG* Norm |
|---|---|---|---|---|---|---|
|
| 9.05 | 11.2 | 8.7 | 0, | 0, | 15.5, |
|
| 78.3 | 81.5 | 77.4 | 0, | 0, | 1.0, |
|
| 72.35 | 78.1 | 70.2 | 0, | 0, | 8.0, |
|
| 43.2 | 48.1 | 43.2 | 0, | 0, | 31, |
|
| 28.7 | 26.5 | 26.7 | 104, | 3.5, | 3.5, |
|
| 91.5 | 87.0 | 86.0 | 62.5, | 0, | 0, |
|
| 4.15 | 4.2 | 4.1 | 78, | 43.5, | 27.5, |
Hematological tests results.
| Indicators | Me1-Me2 (C.G.* E.G.) | Me1-Me2 (C.G.* Norm) | Me1-Me2 (E.G.* Norm) |
|---|---|---|---|
|
| 2.5 CI 95% [2.2; 3.2] | 2.3 CI 95% [1.8; 3.1] | 0.3 CI 95% [0.1; 0.5] |
|
| 4.3 CI 95% [3.5; 5.0] | 3.2 CI 95% [2.3; 3.9] | 0.9 CI 95% [0.4; 1.7] |
|
| 7.7 CI 95% [6.8; 8.2] | 5.7 CI 95% [5.1; 6.2] | 2.0 CI 95% [1.0; 2.4] |
|
| 4.8 CI 95% [4.2; 5.4] | 5.1 CI 95% [4.7; 6.0] | 0.4 CI 95% [-0.2; 1.2] |
|
| 0.1 CI 95% [-0.6; 1.2] | 2.05 CI 95% [1.5; 2.8] | 2.0 CI 95% [1.6; 3.1] |
|
| 1.0 CI 95% [0; 2] | 4.55 CI 95% [3.5; 5.8] | 5.8 CI 95% [4.6; 7.3] |
|
| 0.1 CI 95% [0; 0.2] | 0 CI 95% [-0.1; 0.1] | 0.1 CI 95% [0; 0.2] |